The Karathanasis Laboratory for Nanomedical Engineering (nME lab) focuses on translational cancer nanomedicine. Our research program exploits the engineerable nature of nanoparticle technology to develop clinically relevant therapeutic and imaging agents for hard-to-treat cancers based on the integration of nanotechnology, oncology, imaging science and cancer biology. Specifically, we study the relation between the structure of nanoparticles (e.g., size, shape) and their navigation through different biological processes to extract design parameters that improve the overall in vivo performance of nanomedicines.
Our lab is located at University Hospitals Case Medical Center and is part of the Case Center for Imaging Research and the Case Comprehensive Cancer Center. To learn more about cancer and imaging research at Case, we encourage you to further explore the websites of our lab and its affiliiated centers.
|December 2013 | Our recent manuscript in the Journal of Controlled Release is highlighted on the cover. It is also accompanied by a cover story.|
|November 2013 | Prof. Karathanasis was selected to attend the 2013 National Academies Keck Futures Initiative conference on "The future of advanced nuclear technologies".|
|October 2013 | Researchers aim nanotechnology at micrometastases
|July 2013 | The nME Lab received an RO1 grant from the National Cancer Institute|
|July 2013 | The nME Lab was awarded a grant from the Ohio Cancer Research Associates|
|June 2013 | Aaron Mayer wins a Fulbright National Scholarship|
|Location:||Wearn 310 & 314|
|Email:||stathis at case.edu|